(secondQuint)Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix.

 OBJECTIVES: - Determine the antitumor activity of doxorubicin HCl liposome in patients with persistent or recurrent squamous cell carcinoma of the cervix.

 - Determine the toxicity of this drug in these patients.

 OUTLINE: This is a multicenter study.

 Patients receive doxorubicin HCl liposome IV over 1 hour on day 1.

 Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

 Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

 PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study.

.

 Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix.

